The drug will likely gain approval to be covered by medical benefit schemes across numerous markets. The subsidised price is unlikely to approach the price received by PRR in most instances.
Additionally, the costs are subjective, and many could afford the treatment, even excluding the aid of medical benefit schemes.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.010(4.17%) |
Mkt cap ! $365.0M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 24.0¢ | $1.350M | 5.550M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17018 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 547018 | 11 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |